UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 4)
Synbiotics Corporation
______________________________________________________________________________
(Name of Issuer)
Common Stock, no par value
______________________________________________________________________________
(Title of Class of Securities)
87156610
______________________________________________________________________________
(CUSIP Number)
Roger A. Keller, 675 McDonnell Blvd., P. O. Box 5840
St. Louis, MO 63134
(314) 654-5242
______________________________________________________________________________
(Name, Address and Telephone No. Of Person
Authorized to Receive Notices and Communications)
November 20, 1997
______________________________________________________________________________
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b) (3) or (4), check the following
box. / /
Note: Six copies of this statement, including all exhibits, should be filed
with the Commission. See Rule 13d-1(a) for other parties to whom copies are
to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
______________________________________________________________________________
1. NAME OF REPORTING PERSON
S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Mallinckrodt Inc. 36-1263901
______________________________________________________________________________
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) / /
N/A (b) / /
______________________________________________________________________________
3. SEC USE ONLY
______________________________________________________________________________
4. SOURCE OF FUNDS
00
______________________________________________________________________________
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS
IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
N/A / /
______________________________________________________________________________
6. CITIZENSHIP OR PLACE OF ORGANIZATION
New York
______________________________________________________________________________
7. SOLE VOTING POWER
NUMBER OF 392,639
SHARES _______________________________________________________________
BENEFICIALLY 8. SHARED VOTING POWER
OWNED BY N/A
EACH _______________________________________________________________
REPORTING 9. SOLE DISPOSITIVE POWER
PERSON 392,639
WITH _______________________________________________________________
10. SHARED DISPOSITIVE POWER
N/A
______________________________________________________________________________
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
392,639
______________________________________________________________________________
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES / /
N/A
______________________________________________________________________________
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.8%
______________________________________________________________________________
14. TYPE OF REPORTING PERSON
CO
______________________________________________________________________________
Item 1. Security and Issuer.
This statement relates to the Common Stock, no par value (the "Common
Stock"), of Synbiotics Corporation, a California corporation (the "Issuer"),
whose executive offices are located at 11011 Via Frontera Drive, San Diego, CA
92127.
Item 2. Identity and Background.
Mallinckrodt Inc. is a New York corporation ("Mallinckrodt") whose
principal business is the production and sale of specialty pharmaceutical and
highly selected specialty industrial chemicals; and the production and sale of
human health products in the fields of cardiology, radiology, respiratory
care, anesthesiology, nuclear medicine and critical care. Mallinckrodt's
principal office is located at 675 McDonnell Boulevard, St. Louis, Missouri
63134.
During the last five years, neither Mallinckrodt nor any of its executive
officers, directors or controlling persons has been convicted in a criminal
proceeding (excluding traffic violations or similar misdemeanors).
During the last five years, neither Mallinckrodt nor any of its executive
officers, directors or controlling persons has been and is not now (a) subject
to a judgment, decree or final order enjoining future violations of, or
prohibiting or mandating activities subject to,federal or state securities
laws, or (b) a party to a civil proceeding of a judicial or administrative
body of competent jurisdiction finding any violation with respect to such
laws.
Item 3. Source and Amount of Funds or Other Consideration.
No change from information in Mallinckrodt's prior filings on Schedule
13D with respect to the Common Stock.
Item 4. Purpose of Transaction.
No change from information in Mallinckrodt's prior filings on Schedule
13D with respect to the Common Stock.
Item 5. Interest in Securities of the Issuer.
(a) As of the date of the event which required the filing of this statement
(November 20, 1997), Mallinckrodt beneficially owned 433,639 shares of Common
Stock of the Issuer, representing approximately 5.3% of the issued and
outstanding shares of the Common Stock. As of the date of this filing
(February 16, 1998), Mallinckrodt beneficially owned 392,639 shares of Common
Stock of the Issuer, representing approximately 4.8% of the issued and
outstanding shares of the Common Stock.
(b) Mallinckrodt had voting and dispositive power with respect to all shares
of the Common Stock referenced in response to Item 5(a).
(c) Mallinckrodt engaged in the following sales of the Common Stock in the 60
day period ending on February 16, 1998:
<TABLE>
Date Shares Price Where
<S> <C> <C> <C>
January 2, 1998 1,000 3.063 Open market
January 5, 1998 1,000 3.000 " "
January 6, 1998 1,000 3.000 " "
January 7, 1998 1,000 3.063 " "
January 8, 1998 1,000 3.125 " "
January 9, 1998 1,000 3.188 " "
January 12, 1998 1,000 3.125 " "
January 13, 1998 1,000 3.125 " "
January 14, 1998 1,000 3.125 " "
January 15, 1998 1,000 3.125 " "
January 16, 1998 1,000 3.125 " "
January 20, 1998 1,000 3.188 " "
January 21, 1998 1,000 3.188 " "
January 22, 1998 1,000 3.188 " "
January 23, 1998 1,000 3.188 " "
January 26, 1998 1,000 3.188 " "
January 27, 1998 1,000 3.188 " "
January 28, 1998 1,000 3.188 " "
January 29, 1998 1,000 3.188 " "
January 30, 1998 1,000 3.188 " "
February 2, 1998 1,000 3.188 " "
February 3, 1998 1,000 3.188 " "
February 4, 1998 1,000 3.188 " "
February 6, 1998 1,000 3.188 " "
February 9, 1998 1,000 3.188 " "
February 10, 1998 1,000 3.188 " "
February 11, 1998 1,000 3.156 " "
February 13, 1998 1,000 3.156 " "
</TABLE>
(d) Not applicable.
(e) Mallinckrodt ceased to be the beneficial owner of more than five percent
of the Common Stock on or about January 20, 1998.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect
to Securities of the Issuer.
No change from information contained in Mallinckrodt's prior filings on
Schedule 13D with respect to the Common Stock.
Item 7. Material to be Filed as Exhibits
No change from exhibits filed with Mallinckrodt's prior filings on
Schedule 13D with respect to the Common Stock.
Signature
After reasonable inquiry and to the best of my knowledge and belief, the
undersigned certifies that the information set forth in this statement is
true, complete and correct.
Date: February 16, 1998
MALLINCKRODT INC., a New York corporation
/s/ Roger A. Keller
_______________________________________
Name: Roger A. Keller
Title: Vice President, Secretary & General Counsel
